Literature DB >> 24291067

Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?

Connie Jackaman1, Delia J Nelson2.   

Abstract

Most cancers emerge in elderly and immune-comprised hosts implying an important role for cancer immune surveillance. Here, we focus on the role of tissue-associated innate immune cells including antigen presenting cells (i.e. dendritic cells and macrophages), myeloid derived suppressor cells and neutrophils in healthy and cancer-bearing elderly hosts. Most cancers, including the cancers that we are interested in, i.e. lung carcinomas and mesothelioma, emerge in aging populations at a time when naïve T cell function is declining. CD8(+) cytotoxic T lymphocytes are critical anti-tumor effector cells, and their diminished function may contribute to cancer escape mechanisms in the elderly. Therefore, we compare the likely consequences of innate immune cell interactions with T cells in young versus elderly hosts. We examine data showing that elderly-derived innate cells are highly immunosuppressive and may provide a more tumorigenic milieu than their younger counterparts. Standard chemotherapy often only provides these patients a few extra months survival time. Recent evidence has shown that standard chemotherapy is not as effective in hosts devoid of T cells. Therefore, T cell dysfunction in the elderly may contribute to poor treatment outcomes. However, there is also evidence that T cell immunity can be rejuvenated via activated dendritic cells and/or macrophages. Combining 'rejuvenation' immunotherapy with standard chemotherapy may offer an improved outcome for elderly cancer patients. We explore this potential herein.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Cancer; Chemotherapy; Immunotherapy; Macrophage; Myeloid-derived suppressor cell; Neutrophil

Mesh:

Substances:

Year:  2013        PMID: 24291067     DOI: 10.1016/j.exger.2013.11.009

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  11 in total

Review 1.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

2.  Transparent reporting of experimental parameters in assays measuring phenotypic steps in metastasis.

Authors:  Robin Boiy; Jonas Steenbrugge; Jan Van Deun; An Hendrix; Evelyne Meyer; Olivier De Wever
Journal:  Clin Exp Metastasis       Date:  2018-10-28       Impact factor: 5.150

Review 3.  Myeloid-Derived Suppressor Cells at the Intersection of Inflammaging and Bone Fragility.

Authors:  Keith L Kirkwood; Lixia Zhang; Ramkumar Thiyagarajan; Kenneth L Seldeen; Bruce R Troen
Journal:  Immunol Invest       Date:  2018-11       Impact factor: 3.657

Review 4.  Cancer Immunotherapies: Are They as Effective in the Elderly?

Authors:  Kate Poropatich; Joel Fontanarosa; Sandeep Samant; Jeffrey A Sosman; Bin Zhang
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 4.271

Review 5.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

6.  Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells.

Authors:  Jiang-Qi Liu; Xing-Yong Li; Hai-Qiong Yu; Gui Yang; Zhi-Qiang Liu; Xiao-Rui Geng; Shuai Wang; Li-Hua Mo; Lu Zeng; Miao Zhao; Yun-Ting Fu; Hong-Zhi Sun; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Sci Rep       Date:  2015-06-02       Impact factor: 4.379

7.  A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway.

Authors:  Hao Xue; Guang Yuan; Xing Guo; Qinglin Liu; Jinsen Zhang; Xiao Gao; Xiaofan Guo; Shugang Xu; Tong Li; Qianqian Shao; Shaofeng Yan; Gang Li
Journal:  Autophagy       Date:  2016-05-10       Impact factor: 16.016

Review 8.  Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.

Authors:  Gabor J Szebeni; Csaba Vizler; Lajos I Nagy; Klara Kitajka; Laszlo G Puskas
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

9.  Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.

Authors:  Yue Zhu; Di Fu; Qing Shi; Ziyang Shi; Lei Dong; Hongmei Yi; Zhenhua Liu; Yan Feng; Qian Liu; Hai Fang; Shu Cheng; Li Wang; Qiang Tian; Pengpeng Xu; Weili Zhao
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 10.  How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells.

Authors:  Anna Aiello; Mattia Emanuela Ligotti; Maider Garnica; Giulia Accardi; Anna Calabrò; Fanny Pojero; Hugo Arasanz; Ana Bocanegra; Ester Blanco; Luisa Chocarro; Miriam Echaide; Leticia Fernandez-Rubio; Pablo Ramos; Sergio Piñeiro-Hermida; Grazyna Kochan; Nahid Zareian; Farzin Farzaneh; David Escors; Calogero Caruso; Giuseppina Candore
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.